---
title: >-
  Effectiveness of Early Remdesivir Initiation in Patients with
  Immunocompromising Conditions Hospitalized with COVID-19 by Variant Era, Level
  of Immunocompromise, and Age.
description: >-
  Explore this publication on real-world evidence: Effectiveness of Early
  Remdesivir Initiation in Patients with Immunocompromising Conditions
  Hospitalized with…
date: '2025-01-01'
category: Publications
tags:
  - COVID-19
  - Poster Presentation
  - Care
  - 'No'
  - Methods/Pharmacoepi
  - R&D
canonical_url: >-
  https://www.headwaterscience.com/resources/publications/di-covid-19/effectiveness-of-early-remdesivir-initiation-in-patients/
source: Headwater Science
license: © 2026 Headwater Science. All rights reserved.
slug: effectiveness-of-early-remdesivir-initiation-in-patients
id: 1OtDmlRZ8SOULV5htUeFW4
contentType: article
---

## Challenge

Immunocompromised patients with COVID-19 face higher risks of progression and mortality, but the real-world effectiveness of early remdesivir initiation in this vulnerable subgroup had not been estimated using causal methods.

## Solution

Target RWE researchers applied rigorous causal methods to estimate the effectiveness of early remdesivir initiation in immunocompromised patients hospitalized with COVID-19, addressing time-varying confounding using the clone-censor-weight framework.

## Impact

Demonstrating real-world effectiveness of early remdesivir in immunocompromised COVID-19 patients provides Gilead with targeted post-authorization evidence for this high-priority subgroup.

## Use Cases / Links

Early remdesivir effectiveness evidence in immunocompromised COVID-19 patients for Gilead post-authorization label strategy, Clone-censor-weight application for dynamic treatment protocol effectiveness in vulnerable COVID-19 populations